Outlook Therapeutics Appoints New CFO; Lawrence Kenyon to Depart

What Happened
Outlook Therapeutics, Inc. announced on August 27, 2026 (filed 8‑K) that its Chief Financial Officer, Treasurer, Corporate Secretary and director Lawrence A. Kenyon will cease serving in those executive roles effective September 1, 2026, and will remain employed in a non‑executive role through September 30, 2026. The Board appointed Kevin Lundquist (age 58) as CFO, Treasurer, principal financial officer and principal accounting officer effective September 1, 2026. The company says Kenyon’s departure is not due to any disagreement regarding accounting or financial matters.

Key Details

• Effective date: Kevin Lundquist’s appointment and change in principal officer roles effective September 1, 2026; Kenyon remains employed in a non‑executive role through September 30, 2026 and will step down from the Board by that Separation Date. Board size to be reduced to eight directors upon Kenyon’s board departure.
• Lundquist compensation: initial base salary $450,000; target annual cash bonus = 50% of base salary; participation in benefit plans.
• Equity inducement: grant of a stock option to purchase 500,000 shares (outside but subject to terms of the 2024 Equity Incentive Plan per Nasdaq Rule 5635(c)(4)); 10‑year term; exercise price = fair market value on Transition Date; vesting 25% after one year then monthly over next three years.
• Severance protections: If Lundquist is terminated without cause or resigns for good reason, he is entitled to a lump‑sum payment equal to nine months’ base salary and up to four months of employee benefit coverage (subject to release and restrictive covenants). If a qualifying termination occurs near a change in control (within two months before or six months after), unvested time‑vesting equity would fully vest.
• Kenyon separation: treated as a termination without cause. Subject to signing the Separation Agreement, Kenyon is eligible for a lump sum equal to 12 months’ base salary + $20,000 + his full 2026 target bonus, 100% acceleration of outstanding stock options, and up to 12 months of COBRA benefits. If a change in control occurs within two months after separation, the cash package increases (18 months’ salary + $20,000 + 150% of target bonus) and COBRA extends to 18 months.

Why It Matters
A CFO change is material because it affects who is responsible for the company’s financial reporting and investor communications. The filing details compensation and severance that could create near‑term cash or non‑cash expenses (lump‑sum payments and full acceleration of Kenyon’s options) and potential future dilution from the 500,000‑share option grant to the new CFO. The company explicitly states Kenyon’s departure was not due to disagreements over accounting or controls, which reduces a common investor concern. Investors should note the effective dates, severance amounts, and the potential for accelerated vesting around any change‑of‑control events.